Supplement
Journal of Gastroenterology and Hepatology
Abstracts of Gastroenterological Society of Australia Australian Gastroenterology Week
Volume 32, Issue Supplement S2 Pages 1 - 197, August 2017Journal of Gastroenterology and Hepatology
Abstracts of Gastroenterological Society of Australia Australian Gastroenterology Week
Version of Record online: 17 AUG 2017 | DOI: 10.1111/jgh.13892
Remote consultation referral system: An effective way to treat homeless and marginalized patients with chronic hepatitis C in primary care
Comparison of direct-acting antiviral therapy for hepatitis C between specialist centers and primary care: Efficacy and adherence to response assessment
Discontinuation of nucleoside analogue therapy in e-antigen-negative chronic hepatitis B: A meta-analysis
A real-world experience treating hepatitis C patients with direct-acting antivirals
Need for hepatocellular carcinoma screening during direct-acting antiviral treatment for patients with hepatitis C and cirrhosis
Project ECHO: A novel tele-mentoring service to aid hepatitis C treatment in difficult-to-access populations
Direct-acting antiviral therapy failures in hepatitis C treatment: A tertiary hospital's experience
Applying the REACH-B model to an Australian chronic hepatitis B cohort underestimates the incidence of hepatocellular carcinoma
General practitioners' perspectives on and use of remote consultation referral system for hepatitis C treatment in primary care: Interim results
Hepatitis C viral load at 12 weeks: Only half the story
References
Efficacy, safety, and long-term outcomes in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: TOPAZ-I interim data from Australia
Early experience of direct-acting antiviral treatment for chronic hepatitis C in a needle syringe program outreach service
An eHealth model of care for community hepatitis c management: The HealthElink project
Characteristics and predictors of treatment failure for hepatitis C treatment in the first 12 months of unrestricted use of direct-acting antiviral therapy
Efficacy and outcomes of treatment with direct-acting antiviral therapy: An initial 12-month tertiary experience
Use of APRI to exclude cirrhosis in correctional services: Minimizing need for FibroScan
Mental health care in chronic hepatitis C patients: The unmet need in interferon-free treatment
References
Towards hepatitis C eradication in far north Queensland: A report on models of care and direct-acting antiviral outcomes
Defining a new phase in hepatitis B: The role of viral load in immune escape
Retrospective data analysis to assess the feasibility of transitioning the management of stable chronic hepatitis B from tertiary to primary care
Real-world treatment for hepatitis C in the direct-acting antiviral era: Comparing outcomes between the tertiary liver clinic and community
Outcomes of porphyria cutanea tarda in the era of direct-acting antivirals for hepatitis C infection
Effect of direct-acting antivirals on hepatocellular carcinoma incidence in hepatitis C virus-related cirrhosis
Liver clinic waiting time reduced with the introduction of remote support for hepatitis C treatment in primary care
Long-term outcomes of patients with chronic hepatitis B previously treated with pegylated-interferon
The first year with combination direct-acting antivirals in a real-world cohort from a regional liver clinic in New South Wales
References
Outcomes of treatment for hepatitis C virus infection in the prison setting
Direct-acting antiviral treatment failure is associated with genotype 3 hepatitis C cirrhosis and the selection of NS5A resistance sequences: Implications for salvage therapy
Preliminary results from the HEDGE study: Does the hepatitis C virus cause depression?
Role of point-of-care testing for hepatitis B in culturally and linguistically diverse communities
How well used, effective, and safe is general practitioner prescription of hepatitis C therapy?
Risk of hepatocellular carcinoma among patients with hepatitis C virus cirrhosis treated with direct-acting antiviral therapy: An Australian experience
Hepatitis C and liver disease in opioid treatment program patients
References
High efficacy in patients with chronic hepatitis C virus genotype 1b infection treated with elbasvir–grazoprevir for 12 weeks: An integrated analysis
Can quantitative HBsAg threshold predict high viral load and risk of mother-to-child transmission? Like life, you get what you pay for
“Teach-back” is a simple communication tool that improves health literacy in people with chronic hepatitis B
Chronic hepatitis B infection: 25 years of nucleoside analogue therapy
Real-world Australian data replicate very high sustained virological response at 12 weeks (SVR12) results reported in clinical trials and suggest SVR12 is highly achievable even in those without an end-of-treatment response
Eliminate Hepatitis C Partnership: Clinical site scoping
Quantitative HBeAg levels at Week 24 predict on-treatment serological response to tenofovir disoproxil fumarate therapy in HBeAg-positive patients infected with chronic hepatitis B
Hepatitis B virus activity does not influence the degree of liver steatosis in patients with hepatitis B-related chronic liver disease
References
Australian tertiary hospital real-life experience: Universal access to direct-acting antivirals in a novel treatment model
Discontinuation of nucleoside analogue therapy in e-antigen-negative chronic hepatitis B: A meta-analysis
A real-world experience treating hepatitis C patients with direct-acting antivirals
Need for hepatocellular carcinoma screening during direct-acting antiviral treatment for patients with hepatitis C and cirrhosis
Project ECHO: A novel tele-mentoring service to aid hepatitis C treatment in difficult-to-access populations
Direct-acting antiviral therapy failures in hepatitis C treatment: A tertiary hospital's experience
Applying the REACH-B model to an Australian chronic hepatitis B cohort underestimates the incidence of hepatocellular carcinoma
General practitioners' perspectives on and use of remote consultation referral system for hepatitis C treatment in primary care: Interim results
Hepatitis C viral load at 12 weeks: Only half the story
References
Efficacy, safety, and long-term outcomes in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: TOPAZ-I interim data from Australia
Early experience of direct-acting antiviral treatment for chronic hepatitis C in a needle syringe program outreach service
An eHealth model of care for community hepatitis c management: The HealthElink project
Characteristics and predictors of treatment failure for hepatitis C treatment in the first 12 months of unrestricted use of direct-acting antiviral therapy
Efficacy and outcomes of treatment with direct-acting antiviral therapy: An initial 12-month tertiary experience
Use of APRI to exclude cirrhosis in correctional services: Minimizing need for FibroScan
Mental health care in chronic hepatitis C patients: The unmet need in interferon-free treatment
References
Towards hepatitis C eradication in far north Queensland: A report on models of care and direct-acting antiviral outcomes
Defining a new phase in hepatitis B: The role of viral load in immune escape
Retrospective data analysis to assess the feasibility of transitioning the management of stable chronic hepatitis B from tertiary to primary care
Real-world treatment for hepatitis C in the direct-acting antiviral era: Comparing outcomes between the tertiary liver clinic and community
Outcomes of porphyria cutanea tarda in the era of direct-acting antivirals for hepatitis C infection
Effect of direct-acting antivirals on hepatocellular carcinoma incidence in hepatitis C virus-related cirrhosis
Liver clinic waiting time reduced with the introduction of remote support for hepatitis C treatment in primary care
Long-term outcomes of patients with chronic hepatitis B previously treated with pegylated-interferon
The first year with combination direct-acting antivirals in a real-world cohort from a regional liver clinic in New South Wales
References
Outcomes of treatment for hepatitis C virus infection in the prison setting
Direct-acting antiviral treatment failure is associated with genotype 3 hepatitis C cirrhosis and the selection of NS5A resistance sequences: Implications for salvage therapy
Preliminary results from the HEDGE study: Does the hepatitis C virus cause depression?
Role of point-of-care testing for hepatitis B in culturally and linguistically diverse communities
How well used, effective, and safe is general practitioner prescription of hepatitis C therapy?
Risk of hepatocellular carcinoma among patients with hepatitis C virus cirrhosis treated with direct-acting antiviral therapy: An Australian experience
Hepatitis C and liver disease in opioid treatment program patients
References
High efficacy in patients with chronic hepatitis C virus genotype 1b infection treated with elbasvir–grazoprevir for 12 weeks: An integrated analysis
Can quantitative HBsAg threshold predict high viral load and risk of mother-to-child transmission? Like life, you get what you pay for
“Teach-back” is a simple communication tool that improves health literacy in people with chronic hepatitis B
Chronic hepatitis B infection: 25 years of nucleoside analogue therapy
Real-world Australian data replicate very high sustained virological response at 12 weeks (SVR12) results reported in clinical trials and suggest SVR12 is highly achievable even in those without an end-of-treatment response
Eliminate Hepatitis C Partnership: Clinical site scoping
Quantitative HBeAg levels at Week 24 predict on-treatment serological response to tenofovir disoproxil fumarate therapy in HBeAg-positive patients infected with chronic hepatitis B
Hepatitis B virus activity does not influence the degree of liver steatosis in patients with hepatitis B-related chronic liver disease
References
Australian tertiary hospital real-life experience: Universal access to direct-acting antivirals in a novel treatment model
